The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would
have been antidilutive:
Schedule
of Anti-dilutive Securities
| | |
2026 | | |
2025 | |
| | |
Six months ended June 30, | |
| | |
2026 | | |
2025 | |
| Stock options | |
| 1,076,312 | | |
| 24,012 | |
| Warrants | |
| 17,687 | | |
| 19,457 | |
| Common shares issuable upon conversion of Series F Preferred Stock | |
| 249,624 | | |
| - | |
| Common shares issuable upon conversion of warrants attached to Series H Preferred Stock | |
| 23,925,000 | | |
| - | |
| Common shares issuable upon conversion of Series H Preferred Stock | |
| 15,389,322 | | |
| - | |
| Total | |
| 40,657,945 | | |
| 43,469 | |
|